Innovative approaches to treat steroid-resistant or steroid refractory GVHD.
First-line treatment of GVHD is based on steroids and produces sustained responses in 50-80% of patients with acute GVHD (aGVHD) and 40-50% of patients with chronic GVHD (cGVHD) depending on the initial disease severity. Non-responding children are offered second-line therapy with combinations of various agents, but currently available agents have not improved survival in these high-risk populations. In this minireview, we will focus on new agents to treat GVHD in paediatric patients.
Berger
M
M
Paediatric Onco-Haematology and Stem Cell Transplantation and Cellular Therapy Unit, Regina Margherita Children's Hospital, Turin, Italy.
Biasin
E
E
Saglio
F
F
Fagioli
F
F
D000208:Acute Disease; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D018572:Disease-Free Survival; D004351:Drug Resistance; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D013256:Steroids
D013256:Steroids